



## OPEN ACCESS

EDITED AND REVIEWED BY  
Luis Ignacio Gonzalez-Granado,  
University Hospital October 12, Spain

## \*CORRESPONDENCE

Huihua Ding  
✉ dinghuihua@outlook.com  
Qiong Fu  
✉ fuqiong5@163.com

<sup>†</sup>These authors are co-first authors and  
contribute equally to this paper

RECEIVED 10 December 2025  
REVISED 10 December 2025  
ACCEPTED 11 December 2025  
PUBLISHED 16 December 2025

## CITATION

Wu C, Wang Y, Chen S, Lin Y, Du F, Wang X,  
Chen S, Lu L, Ye S, Ding H and Fu Q (2025)  
Correction: Obinutuzumab in systemic lupus  
erythematosus: a real-world experience.  
*Front. Immunol.* 16:1764419.  
doi: 10.3389/fimmu.2025.1764419

## COPYRIGHT

© 2025 Wu, Wang, Chen, Lin, Du, Wang, Chen,  
Lu, Ye, Ding and Fu. This is an open-access  
article distributed under the terms of the  
[Creative Commons Attribution License \(CC BY\)](#).  
The use, distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in  
this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Correction: Obinutuzumab in systemic lupus erythematosus: a real-world experience

Chunmei Wu<sup>1†</sup>, Yinglu Wang<sup>1†</sup>, Shenshen Chen<sup>1</sup>, Yanwei Lin<sup>1</sup>,  
Fang Du<sup>1</sup>, Xiaodong Wang<sup>1</sup>, Sheng Chen<sup>1</sup>, Liangjing Lu<sup>1</sup>,  
Shuang Ye<sup>1</sup>, Huihua Ding<sup>1\*</sup> and Qiong Fu<sup>1,2\*</sup>

<sup>1</sup>Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine,  
Shanghai, China, <sup>2</sup>Shanghai Immune Therapy Institute, Shanghai, China

## KEYWORDS

systemic lupus - erythematosus, obinutuzumab, biologics, real world study,  
B cell depletion

## A Correction on

## Obinutuzumab in systemic lupus erythematosus: a real-world experience

By Wu C, Wang Y, Chen S, Lin Y, Du F, Wang X, Chen S, Lu L, Ye S, Ding H and Fu Q (2025) *Front. Immunol.* 16:1702550. doi: 10.3389/fimmu.2025.1702550

There was a mistake in **Table 1** as published. The percentage given for the ‘Relapsing’ column was erroneously written as “27 (55.4)”. This has been corrected to read “27 (48.2)”. The percentage given for the “musculoskeletal involvement” column was erroneously written as “9 (16.1)”. This has been corrected to read “10 (17.9)”. The corrected **Table 1** appears below.

In the **Abstract**, two percentages were reported incorrectly in the first sentence of the **Results** section. This has been corrected to read:

“At baseline, 35.7% of patients were newly diagnosed, 55.4% had relapsing/refractory disease, and 8.9% were on maintenance therapy.”

A correction has been made to section **Results**, paragraph 2, to change “Besdieds” to “Besides”:

“Besides, antidsDNA antibody levels decreased, while complement levels exhibited a notable upward trend throughout the follow-up period.”

A correction has been made to section **Results**, paragraph 2, to change maitained” to “maintained”:

“Subgroups analysis revealed that all three subgroups, especially the new-onset and relapsing/refractory groups, showed a rapid decrease in SLEDAI-2K scores, which were maintained at low levels through week 48.”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 Baseline characteristics of SLE patients treated with obinutuzumab.

SLE Patients (n=56)	
Epidemiologic features	
Female, n (%)	45 (80.3)
Disease duration at first treatment, mean ± SD, (months)	48.52 ± 49.32 (0.3-168)
Disease state, n (%)	
New-onset	20 (35.7)
Relapsing	27 (48.2)
Refractory	4 (7.1)
Maintenance	5 (8.9)
Age at obinutuzumab treatment, mean ± SD, (years)	30.98 ± 12.45 (13-65)
Clinical features, n (%)	
Fever	15 (26.8)
Mucocutaneous involvement	20 (35.7)
Musculoskeletal involvement	10 (17.9)
Serositis	19 (33.9)
Hematologic abnormalities	30 (53.6)
Autoimmune hemolytic anemia	12 (21.4)
Hemoglobin level≤60g/L	3 (25.0)
Immune thrombocytopenia	15 (26.8)
Plate level≤30×10 <sup>9</sup> /L	5 (33.3)
Leukocytopenia	5 (8.9)
Lupus nephritis	15 (26.8)
24-hour urine protein, mean ± SD, (g/24h)	2.28 ± 0.49 (0.67-6.09)
Serum creatinine, mean ± SD, (μmol/L)	83.83 ± 41.29 (32-185)
Neuropsychiatric lupus	18 (32.1)
Gastrointestinal vasculitis	5 (8.9)
Pulmonary hypertension	4 (7.1)
Thrombotic microangiopathy	4 (7.1)
Myocardial involvement	2 (3.6)
Antiphospholipid syndrome	
Deep venous thrombosis	7 (12.5)
Cerebral infraction	3 (5.4)
Pulmonary embolism	1 (1.8)

(Continued)

TABLE 1 Continued

SLE Patients (n=56)	
Serologic characterization	
WBC, mean $\pm$ SD, ( $\times 10^9$ /L)	8.10 $\pm$ 4.29 (1.02-21.72)
Hb, mean $\pm$ SD, (g/L)	104.89 $\pm$ 26.06 (51.00-154.00)
PLT, mean $\pm$ SD, ( $\times 10^9$ /L)	167.71 $\pm$ 120.57 (2.00-494.00)
C3, mean $\pm$ SD, (g/L)	0.65 $\pm$ 0.28 (0.19-1.34)
C4, mean $\pm$ SD, (g/L)	0.12 $\pm$ 0.10 (0.02-0.66)
IgA, mean $\pm$ SD, (g/L)	2.57 $\pm$ 1.26 (0.27-6.55)
IgM, mean $\pm$ SD, (g/L)	1.03 $\pm$ 0.70 (0.21-3.00)
IgG, mean $\pm$ SD, (g/L)	16.7 $\pm$ 8.9 (6.15-53.90)
Anti-dsDNA (ELASA), mean $\pm$ SD, (IU/mL)	167.90 $\pm$ 131.26 (22.46-505.06)
Anti-dsDNA (RIA), mean $\pm$ SD, (IU/mL)	51.66 $\pm$ 35.32 (4.96-100)
Antinuclear antibody positivity, n (%)	56 (100.0)
Anti-SSA positivity, n (%)	28 (50.0)
Anti-Ro52 positivity, n (%)	23 (41.1)
Anti-SSB positivity, n (%)	7 (12.5)
Anti-U1RNP positivity, n (%)	20 (35.7)
Anti-Sm positivity, n (%)	7 (12.5)
Anti-Rib-P positivity, n (%)	15 (26.8)
Anti-Histone positivity, n (%)	12 (21.4)
Antiphospholipid antibody positivity, n (%)	37 (66.1)
B lymphocyte levels	
B lymphocyte percentage, mean $\pm$ SD, (%)	17.76 $\pm$ 12.07 (1.62-44.98)
B lymphocyte count, mean $\pm$ SD, (cells/ $\mu$ L)	247.65 $\pm$ 293.74 (13.10-1268.40)
Disease activity	
SLEDAI-2K, mean $\pm$ SD	11.75 $\pm$ 9.31(0-46)
PGA, mean $\pm$ SD	1.66 $\pm$ 0.87 (0-3)
Previous treatments, n (%)	
Glucocorticoid	48 (85.7)
Hydroxychloroquine	41 (73.2)
Immunosuppressants	33 (58.9)
MMF	20 (35.7)
TAC	14 (25.0)
CTX	9 (16.1)
CsA	8 (14.3)
LEF	6 (10.7)
MTX	5 (8.9)
Tripterygium glycosides	1 (1.8)
AZA	1 (1.8)

(Continued)

TABLE 1 Continued

SLE Patients (n=56)	
Biologics	15 (26.8)
RTX	11 (19.6)
Belimumab	5 (8.9)
Telitacicept	2 (3.6)

SD, standard deviation; SEM, standard error of the mean; MMF, Mycophenolate mofetil; TAC, Tacrolimus; CTX, Cyclophosphamide; CsA, Cyclosporine A; LEF, Leflunomide; MTX, Methotrexate; AZA, Azathioprine; RTX, Rituximab; ELISA, Enzyme-Linked Immunosorbent Assay; RIA, Radioimmunoassay.